Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Last Close
Oct 11 04:00PM ET
2.56
Dollar change
+0.09
Percentage change
3.64
%
Index- P/E- EPS (ttm)-4.97 Insider Own65.18% Shs Outstand4.91M Perf Week-6.23%
Market Cap21.73M Forward P/E- EPS next Y-1.38 Insider Trans85.10% Shs Float2.96M Perf Month-29.86%
Income-25.90M PEG- EPS next Q-0.82 Inst Own12.25% Short Float1.10% Perf Quarter-48.80%
Sales0.00M P/S- EPS this Y-81.30% Inst Trans- Short Ratio0.77 Perf Half Y-29.09%
Book/sh2.30 P/B1.11 EPS next Y69.06% ROA-89.41% Short Interest0.03M Perf Year-28.89%
Cash/sh3.29 P/C0.78 EPS next 5Y- ROE-117.35% 52W Range2.08 - 6.75 Perf YTD-30.75%
Dividend Est.- P/FCF- EPS past 5Y69.13% ROI-136.02% 52W High-62.07% Beta-0.27
Dividend TTM- Quick Ratio2.94 Sales past 5Y0.00% Gross Margin- 52W Low23.08% ATR (14)0.29
Dividend Ex-Date- Current Ratio2.94 EPS Y/Y TTM83.52% Oper. Margin0.00% RSI (14)30.50 Volatility10.51% 9.72%
Employees8 Debt/Eq0.01 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price16.00
Option/ShortNo / Yes LT Debt/Eq0.01 EPS Q/Q-1176.22% Payout- Rel Volume0.65 Prev Close2.47
Sales Surprise- EPS Surprise-30.28% Sales Q/Q- EarningsAug 14 BMO Avg Volume42.13K Price2.56
SMA20-15.03% SMA50-24.89% SMA200-36.13% Trades Volume27,538 Change3.64%
Date Action Analyst Rating Change Price Target Change
Jun-15-20Initiated H.C. Wainwright Buy $20
Oct-01-24 08:01AM
Sep-30-24 08:01AM
Sep-03-24 08:01AM
Aug-14-24 08:01AM
04:32AM
08:01AM Loading…
Aug-13-24 08:01AM
Aug-06-24 08:01AM
Jul-30-24 08:01AM
Jul-17-24 07:00AM
Jul-16-24 07:00AM
Jul-11-24 08:01AM
Jun-27-24 06:53AM
Jun-26-24 09:06AM
Jun-25-24 05:08PM
Jun-24-24 08:01AM
08:01AM Loading…
Jun-22-24 08:01AM
May-22-24 08:01AM
May-09-24 01:53PM
08:01AM
Apr-30-24 08:01AM
Apr-17-24 08:05AM
Apr-01-24 08:01AM
Mar-28-24 08:01AM
Mar-13-24 08:01AM
Mar-04-24 08:01AM
Feb-29-24 08:01AM
Feb-12-24 08:01AM
Feb-01-24 08:01AM
Jan-18-24 08:01AM
Jan-09-24 08:30AM
08:01AM Loading…
Jan-02-24 08:01AM
Dec-28-23 08:45AM
Dec-19-23 08:43AM
Dec-15-23 08:35AM
Dec-12-23 01:02PM
Dec-01-23 08:31AM
Nov-13-23 04:05PM
Nov-06-23 08:05AM
Oct-17-23 08:01AM
Sep-15-23 08:01AM
Aug-14-23 08:01AM
Aug-09-23 04:05PM
Aug-03-23 08:01AM
Aug-02-23 08:01AM
Jun-27-23 08:01AM
Jun-13-23 08:01AM
May-12-23 08:00AM
May-02-23 08:01AM
Apr-03-23 08:00AM
Mar-30-23 04:40PM
Jan-18-23 08:00AM
Nov-08-22 04:05PM
Nov-04-22 09:15AM
Sep-29-22 08:30AM
Sep-15-22 08:30AM
Sep-12-22 09:15AM
May-06-22 08:00AM
Apr-01-22 08:00AM
Mar-15-22 08:00AM
Jan-28-22 04:30PM
Nov-15-21 08:00AM
Nov-04-21 08:00AM
Oct-13-21 08:00AM
Oct-05-21 01:13PM
Oct-01-21 08:00AM
Sep-03-21 11:27AM
Aug-16-21 08:00AM
Jul-12-21 08:30AM
May-17-21 05:02PM
Apr-15-21 04:52PM
Mar-24-21 08:00AM
Mar-05-21 08:30AM
Jan-21-21 04:05PM
Jan-19-21 08:00AM
Jan-06-21 08:30AM
Dec-21-20 05:08AM
Nov-13-20 04:30PM
Sep-02-20 08:30AM
Aug-11-20 03:00PM
Jun-16-20 04:05PM
May-26-20 08:30AM
May-20-20 04:29PM
Apr-21-20 08:30AM
Apr-16-20 04:22PM
Apr-14-20 09:15AM
Mar-31-20 11:04AM
Mar-30-20 04:30PM
Jan-13-20 09:00AM
Jan-10-20 05:00PM
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. Its pipeline includes ANA001, a proprietary oral niclosamide formulation, Gemcabene, which is assessed as an acute indication for COVID-19, NB-01, a treatment for painful diabetic neuropathy, and NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases. The company was founded on October 30, 2014 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DONG-A ST CO., LTD10% OwnerSep 12 '24Sale3.754071,5265,347,792Sep 20 04:20 PM
DONG-A ST CO., LTD10% OwnerJun 23 '24Buy3.132,544,5307,964,3795,348,229Jun 25 04:16 PM